KIR3DL1 and B-cell chronic lymphocytic leukemia: Studies on inhibitory KIRs in CLL-derived NK cells have reported that the expression levels of KIR2DL2/3 and KIR3DL1 are similar in NK cells from CLL patients and healthy individuals and remain stable during disease progression [34,37].